Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talacotuzumab
- Development stage
- Phase 3
- Lead developer
- Janssen Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Talacotuzumab is a humanized IgG1 monoclonal antibody that targets the alpha subunit of the interleukin-3 receptor (CD123, also known as IL3RA). It has been engineered to have increased affinity for CD16 on natural killer cells, thereby enhancing antibody-dependent cellular cytotoxicity (ADCC) against CD123-expressing cells. Talacotuzumab was developed primarily for hematologic malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with clinical trials investigating its use in patients not eligible for intensive chemotherapy. The drug acts by binding to CD123, inhibiting downstream IL-3 signaling and promoting immune-mediated destruction of malignant cells[1][2][4][5].
- Brand names
- talacotuzumab
- Other names
- talacotuzumab
02
Targets
IL3RA (Interleukin 3 Receptor)FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on talacotuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talacotuzumab.